Author’s Reply to Srinivas: “Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modeling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection”

被引：0
|
作者：
Florence Namour
机构：
[1] Galapagos SASU,
来源：
Clinical Pharmacokinetics | 2015年 / 54卷
关键词：
Active Metabolite; Maximum Plasma Concentration; Population Pharmacokinetic Model; Population Pharmacokinetic Analysis; JAK1 Inhibitor;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1297 / 1298
页数：1
相关论文
共 45 条
  • [1] Author's Reply to Srinivas: "Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modeling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection"
    Namour, Florence
    CLINICAL PHARMACOKINETICS, 2015, 54 (12) : 1297 - 1298
  • [2] Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modeling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection
    Florence Namour
    Paul Matthias Diderichsen
    Eugène Cox
    Béatrice Vayssière
    Annegret Van der Aa
    Chantal Tasset
    Gerben Van‘t Klooster
    Clinical Pharmacokinetics, 2015, 54 : 859 - 874
  • [3] Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modeling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection
    Namour, Florence
    Diderichsen, Paul Matthias
    Cox, Eugene
    Vayssiere, Beatrice
    Van der Aa, Annegret
    Tasset, Chantal
    Van't Klooster, Gerben
    CLINICAL PHARMACOKINETICS, 2015, 54 (08) : 859 - 874
  • [4] Comment on: “Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modelling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection”
    Nuggehally R. Srinivas
    Clinical Pharmacokinetics, 2015, 54 : 1293 - 1295
  • [5] Comment on: "Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modelling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection"
    Srinivas, Nuggehally R.
    CLINICAL PHARMACOKINETICS, 2015, 54 (12) : 1293 - 1295
  • [6] Influence of Age and Renal Impairment on Pharmacokinetics of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor
    Florence, Namour
    Fagard, Liesbeth
    Van der Aa, Annegret
    Goss, Sandy
    Harrison, Pille
    Tasset, Chantal
    ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [7] Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, Shows Similar Pharmacokinetics and Pharmacodynamics Profiles in Japanese and Caucasian Healthy Volunteers
    Florence, Namour
    Vayssiere, Beatrice
    Galien, Rene
    Fagard, Liesbeth
    Van der Aa, Annegret
    Goss, Sandy
    Harrison, Pille
    Tasset, Chantal
    ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [8] Preclinical Characterization of GLPG0634, a Selective Inhibitor of JAK1, for the Treatment of Inflammatory Diseases
    Van Rompaey, Luc
    Galien, Rene
    van der Aar, Ellen M.
    Clement-Lacroix, Philippe
    Nelles, Luc
    Smets, Bart
    Lepescheux, Lien
    Christophe, Thierry
    Conrath, Katja
    Vandeghinste, Nick
    Vayssiere, Beatrice
    De Vos, Steve
    Fletcher, Stephen
    Brys, Reginald
    van 't Klooster, Gerben
    Feyen, Jean H. M.
    Menet, Christel
    JOURNAL OF IMMUNOLOGY, 2013, 191 (07): : 3568 - 3577
  • [9] An Active Metabolite Contributes To The Pharmacodynamics and Efficacy Of GLPG0634, a Selective JAK1 Inhibitor
    Namour, Florence
    ARTHRITIS AND RHEUMATISM, 2013, 65 : S765 - S765
  • [10] FILGOTINIB (GLPG0634), A SELECTIVE JAK1 INHIBITOR, SHOWS SIMILAR PK AND PD PROFILES IN JAPANESE AND CAUCASIAN HEALTHY VOLUNTEERS
    Namour, F.
    Vayssiere, B.
    Galien, R.
    Fagard, L.
    Van der Aa, A.
    Harrison, P.
    Tasset, C.
    ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 1063 - 1064
12345